Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Respuesta humoral inducida por la vacuna BBIBP-CorV/Sinopharm COVID-19 en trabajadores de primera línea

  • Raúl Montalvo Otivo
  • , Kelina Almora-León
  • , Anibal Diaz-Lazo
  • , José Beraun-Barrantes
  • , M. Tresierra-Ayala
  • , Josdan Montalvo

    Producción científica: Contribución a una revistaArtículorevisión exhaustiva

    1 Cita (Scopus)

    Resumen

    With the arrival of the vaccine against COVID-19, the decrease in cases of SARS-CoV-2 infection was evidenced. The objective of the study was to quantify the production of neutralizing antibodies (An) and immunoglobulin G (S-IgG) in frontline workers immunized with two doses of the BBIBP-CorV/Sinopharma vaccine. A cross-sectional analytical observational study was carried out in health personnel immunized with the inactivated vaccine (BBIBP-CorV). Their blood samples were collected three months after the second dose, to measure antibody responses (An, S-IgG). Of a total of 172 people evaluated, 110 (64%) people already had COVID-19 before entering the study, An titers were greater than 10 AU/mL in 60.5% of those vaccinated and 89, 3% showed S-IgG greater than 50 AU/mL. Workers older than 60 years were the group that did not develop enough antibodies. The correlation of An and S-IgG was positive (r=0.84) (p<0.001). The administration of two doses of the inactivated BBIBP-CorV/Sinopharma vaccine caused a notable An and S-IgG response, except in those over 60 years of age.

    Título traducido de la contribuciónBBIBP-CorV/Sinopharm COVID-19 vaccine-induced humoral response in frontline workers
    Idioma originalEspañol
    Páginas (desde-hasta)436-443
    Número de páginas8
    PublicaciónBoletin de Malariologia y Salud Ambiental
    Volumen62
    N.º3
    DOI
    EstadoPublicada - 1 may. 2022

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. ODS 3: Salud y bienestar
      ODS 3: Salud y bienestar

    Palabras clave

    • BBIBP-CorV/Sinopharma
    • COVID-19
    • SARS-CoV-2
    • immunoglobulin G
    • neutralizing antibodies
    • vaccines

    Huella

    Profundice en los temas de investigación de 'Respuesta humoral inducida por la vacuna BBIBP-CorV/Sinopharm COVID-19 en trabajadores de primera línea'. En conjunto forman una huella única.

    Citar esto